Hepatitis D screening: Difference between revisions
Joao Silva (talk | contribs) |
m (Changes made per Mahshid's request) |
||
Line 20: | Line 20: | ||
[[Category:Hepatitis|D]] | [[Category:Hepatitis|D]] | ||
[[Category:Viruses]] | [[Category:Viruses]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Revision as of 17:56, 18 September 2017
Hepatitis D |
Diagnosis |
Treatment |
Hepatitis D screening On the Web |
American Roentgen Ray Society Images of Hepatitis D screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2] Jolanta Marszalek, M.D. [3]
Overview
The general population, with low risk of HBV and HDV infection does not need to be screened. However, individuals known to be HBsAg positive, with acute or chronic hepatitis, or those HBsAg negative, but who are IgM anti-HBc positive, should be screened for HDV. Blood products should also be screened in order to avoid transmission of the virus through blood transfusions or hemodialysis.
Screening
The following groups of patients should be screened for hepatitis D:
- Patients known to be HBsAg positive, who have acute or chronic hepatitis
- Patients who have acute hepatitis B, who are not HBsAg positive and who are IgM anti-HBc positive
The general population, without risk for HBV and HDV does not need to be screened.
Blood products should also be screened for the presence of HDV and HBV, in order to prevent infection by blood transfusion and hemodialysis.[1]
For recommendations regarding HBV and HCC screening, refer to Hepatitis B screening[2]
References
- ↑ Hughes SA, Wedemeyer H, Harrison PM (2011). "Hepatitis delta virus". Lancet. 378 (9785): 73–85. doi:10.1016/S0140-6736(10)61931-9. PMID 21511329.
- ↑ Lok AS, McMahon BJ (2004). "[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines]" (PDF). Romanian Journal of Gastroenterology. 13 (2): 150–4. PMID 15229781. Retrieved 2012-02-10. Unknown parameter
|month=
ignored (help)